Very mild muscular dystrophy associated with the deletion of 46% of dystrophin
The DOI matches its Crossref record; 25 of the 25 references it cites were found in a registry or an index.
Abstract
Duchenne muscular dystrophy (DMD) and Becker muscular dystrophy (BMD), a much milder form of the disease where the age of onset can sometimes be as late as the third or fourth decade of life, are caused by mutations in the same X-linked gene, a 14 kilobase (kb) transcript which is spread over more than 2 megabases of the human X chromosome. The corresponding protein, dystrophin, has a relative molecular mass of 400,000. Most mutations causing DMD and BMD are deletions and deletions associated with both phenotypes are observed throughout the gene sequence. This observation led to the suggestion that DMD patients possess deletions that disrupt the reading frame of the protein, whereas BMD patients have deletions that retain the translational reading frame and enable the muscle cells to produce altered dystrophin products. This theory is supported by immunoblotting studies, which show that DMD patients lack dystrophin in their muscle cells or that dystrophin is present at very low levels, whereas BMD patients produce a protein with reduced abundance or abnormal size. Here we describe a deletion of the dystrophin gene in a family segregating for very mild BMD, one member of which was still ambulant at age 61 years, which removes a central part of the dystrophin gene encompassing 5,106 base pairs of coding sequence, almost half the coding information. Immunological analysis of muscle from one of the patients demonstrates that this mutation results in the production of a truncated polypeptide localized correctly in the muscle cell. These results are particularly significant in the context of gene therapy which, if it is ever envisaged, would be facilitated by the replacement of the very large dystrophin gene with a more manipulatable mini-gene construct.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“For example, many shortened versions of the Duchenne muscular dystrophy gene (DMD; 2.3 Mb; 79-exons; 3685 amino acids; 11,055 bp) do not rescue the Duchenne muscular dystrophy phenotype in muscle cells except for the micro-dystrophin for which was reported a milder clinical phenotype [183,184].”
From Recombinant Adeno-Associated Viral Vectors (rAAV)-Vector Elements in Ocular Gene Therapy Clinical Trials and Transgene Expression and Bioactivity Assays (2020) · cites this paper as [184]
Citations
Cites
Dystrophin: the protein product of the Duchenne muscular dystrophy locus
Hoffman, E. P., Brown, R. H., & Kunkel, L. M. (1987) · Cell · doi:10.1016/0092-8674(87)90579-4 · Cited by 4,693
Koenig, M., Hoffman, E. P., Bertelson, C. J., Monaco, A. P., Feener, C., & Kunkel, L. M. (1987) · Cell · doi:10.1016/0092-8674(87)90504-6 · Cited by 2,411
Monaco, A. P., Bertelson, C. J., Liechti-Gallati, S., Moser, H., & Kunkel, L. M. (1988) · Genomics · doi:10.1016/0888-7543(88)90113-9 · Cited by 1,210
Koenig, M., Beggs, A. H., Moyer, M., Scherpf, S., Heindrich, K., Bettecken, T., Meng, G., Müller, C. R., Lindlöf, M., Kääriäinen, H. A., et al. (1989) · Europe PMC (PubMed Central) · Cited by 961
Hoffman, E. P., Fischbeck, K. H., Brown, R. H., Johnson, M., Medori, R., Loire, J. D., Harris, J. B., Waterston, R., Brooke, M., Specht, L., et al. (1988) · New England Journal of Medicine · doi:10.1056/nejm198805263182104 · Cited by 927
Self-citationThe Duchenne muscular dystrophy gene product is localized in sarcolemma of human skeletal muscle
Zubrzycka-Gaarn, E. E., Bulman, D. E., Karpati, G., Burghes, A. H. M., Belfall, B., Klamut, H. J., Talbot, J., Hodges, R. S., Ray, P. N., & Worton, R. G. (1988) · Nature · doi:10.1038/333466a0 · Cited by 658
Self-citationAn autosomal transcript in skeletal muscle with homology to dystrophin
Love, D. R., Hill, D. F., Dickson, G., Spurr, N. K., Byth, B. C., Marsden, R. F., Walsh, F. S., Edwards, Y. H., & Davies, K. E. (1989) · Nature · doi:10.1038/339055a0 · Cited by 494
Self-citationAnalysis of deletions in DNA from patients with Becker and Duchenne muscular dystrophy
co-authors, & Kunkel, L. M. (1986) · Nature · doi:10.1038/322073a0 · Cited by 474
Immunoelectron microscopic localization of dystrophin in myofibres
Watkins, S. C., Hoffman, E. P., Slayter, H. S., & Kunkel, L. M. (1988) · Nature · doi:10.1038/333863a0 · Cited by 449
Davies, K. E., Pearson, P. L., Harper, P. S., Murray, J. M., O'Brien, T., Sarfarazi, M., & Williamson, R. (1983) · Nucleic Acids Research · doi:10.1093/nar/11.8.2303 · Cited by 397
Self-citation
Research works printed but not linked: 5
- Darras, B. T. & Francke, U. Am. J. hum. Genet. 43, 612–619 (1988).
- Love, D. R. & Davies, K. E. Molec biol. Med. 6, 7–17 (1989).
- Davies, K. E. et al. J. Med. Genet. 99, 99 (1987).
- Koenig, M., et al. Am. J. hum. Genet. 45, 498–506 (1989).
- Den Dunnen, J. T. Am. J. hum. Genet, in the press.
Cited by
Items 301–400 of 617
Dystrophin's central domain forms a complex filament that becomes disorganized by in-frame deletions
Delalande, O., Molza, A.-E., Morais, R. D. S., Cheron, A., Pollet, É., Raguénès‐Nicol, C., Tascon, C., Giudice, E., Guilbaud, M., Nicolas, A., et al. (2018) · Journal of Biological Chemistry · doi:10.1074/jbc.m117.809798 · Cited by 31
From diagnosis to therapy in Duchenne muscular dystrophy
Babbs, A., Chatzopoulou, M., Edwards, B., Squire, S. E., Wilkinson, I. V. L., Wynne, G. M., Russell, A. J., & Davies, K. E. (2020) · Biochemical Society Transactions · doi:10.1042/bst20190282 · Cited by 31
Self-citationDetecting Copy Number Changes in Genomic DNA: MAPH and MLPA
White, S. J., Breuning, M. H., & den Dunnen, J. T. (2004) · Methods in cell biology · doi:10.1016/s0091-679x(04)75032-3 · Cited by 33
Exon skipping and Duchenne muscular dystrophy: Hope, hype and how feasible?
Wilton, S. D., & Fletcher, S. (2008) · Neurology India · doi:10.4103/0028-3886.43443 · Cited by 35
“The identification of a very mildly affected BMD patient with an in-frame deletion of almost half the gene prompted the construction of a vector containing the dystrophin minigene.[27] Elegant studies have shown that multiple dystrophin domains can be trimmed to create microdystrophin isoforms.”
BackgroundThe emerging family of dystrophin-related proteins
Blake, D. J., Tinsley, J. M., & Davies, K. E. (1994) · Trends in Cell Biology · doi:10.1016/0962-8924(94)90034-5 · Cited by 28
Self-citationMondin, L., Balghi, H., Constantin, B., Cognard, C., & Sebille, S. (2009) · American Journal of Physiology-Cell Physiology · doi:10.1152/ajpcell.00048.2009 · Cited by 29
Jáni, Á., Lochmüller, H., Acsádi, G., Simoneau, M., Huard, J., Garnier, A., Karpati, G., & Massie, B. (1997) · Journal of Virological Methods · doi:10.1016/s0166-0934(96)02138-6 · Cited by 35
Duan, D. (2016) · Human Gene Therapy Clinical Development · doi:10.1089/humc.2016.001 · Cited by 31
“Clinical observations in mild Becker patients suggest that a successful gene therapy may allow ambulation to the age of 60s.(19) For late-stage boys, the goal of gene therapy is to improve life quality.”
The emerging role of viral vectors as vehicles for DMD gene editing
Maggio, I., Chen, X., & Gonçalves, M. A. F. V. (2016) · Genome Medicine · doi:10.1186/s13073-016-0316-x · Cited by 27
Duan, D. (2006) · PubMed · Cited by 26
Rapid mapping by transposon mutagenesis of epitopes on the muscular dystrophy protein, dystrophin
Sedgwick, S. G., Mân, N. T., Ellis, J. M., Crowne, H. M., & Morris, G. E. (1991) · Nucleic Acids Research · doi:10.1093/nar/19.21.5889 · Cited by 26
Differential stabilities of alternative exon-skipped rod motifs of dystrophin
Ruszczak, C., Mirza, A. A., & Menhart, N. (2009) · Biochimica et Biophysica Acta (BBA) - Proteins and Proteomics · doi:10.1016/j.bbapap.2009.02.016 · Cited by 25
“This last problem is of course again a function of its large size, and current clinical trials are considering an edited dystrophin rod[12,13], based upon a fortuitously discovered natural deletion mutation from a patient with a very mild form of Becker’s muscular dystrophy (BMD, a related condition in which dystrophi…”
BackgroundMarchand, E., Constantin, B., Balghi, H., Claudepierre, M., Cantereau, A., Magaud, C., Mouzou, A., Raymond, G., Braun, S., & Cognard, C. (2004) · Experimental Cell Research · doi:10.1016/j.yexcr.2004.02.032 · Cited by 25
Multiple exon skipping strategies to by-pass dystrophin mutations
Adkin, C. F., Meloni, P. L., Fletcher, S., Adams, A. M., Muntoni, F., Wong, B. L. Y., & Wilton, S. D. (2011) · Neuromuscular Disorders · doi:10.1016/j.nmd.2011.10.007 · Cited by 25
“Some large in-frame DMD deletions are associated with a mild phenotype, however this is greatly dependent upon the location of the DMD mutation [39,40].”
Wu, B., Benrashid, E., Lu, P., Cloer, C., Zillmer, A., Shaban, M., & Lu, Q. L. (2011) · PLoS ONE · doi:10.1371/journal.pone.0019906 · Cited by 25
CRISPR for Neuromuscular Disorders: Gene Editing and Beyond
Young, C. S., Pyle, A. D., & Spencer, M. J. (2019) · Physiology · doi:10.1152/physiol.00012.2019 · Cited by 35
“Through human and mouse studies, it has been demonstrated that not all of the large middle-rod domain of dystrophin is required for its function (35, 38).”
BackgroundRecombinant micro-genes and dystrophin viral vectors
Dickson, G., Roberts, M. L., Wells, D. J., & Fabb, S. A. (2002) · Neuromuscular Disorders · doi:10.1016/s0960-8966(02)00080-9 · Cited by 25
“[1] England SB, Nicholson LV, Johnson MA, et al.”
BackgroundMethodThe dystrophin-associated glycoprotein complex: What parts can you do without?
Sweeney, H. L., & Barton, E. R. (2000) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.011510597 · Cited by 35
Roberts, M. L. (2002) · Human Molecular Genetics · doi:10.1093/hmg/11.15.1719 · Cited by 25
“In an attempt to correct the dystrophic phenotype observed in mdx mice, we chose to express a truncated 3.7 kb micro-dystrophin construct (Fig. 1A) ( 5 ).”
BackgroundInfluentialIn vitro expressed dystrophin fragments do not associate with each other
Chan, Y.-M. M., & Kunkel, L. M. (1997) · FEBS Letters · doi:10.1016/s0014-5793(97)00454-7 · Cited by 25
Recombinant Truncated Dystrophin Minigenes: Construction, Expression, and Adenoviral Delivery
Clemens, P. R., Krause, T. L., Chan, S., Korb, K. E., Graham, F. L., & Caskey, C. T. (1995) · Human Gene Therapy · doi:10.1089/hum.1995.6.11-1477 · Cited by 26
Molecular Diagnosis and Modern Management of Duchenne Muscular Dystrophy
Miller, R. G., & Hoffman, E. P. (1994) · Neurologic Clinics · doi:10.1016/s0733-8619(18)30072-0 · Cited by 25
Synthesis and Characterization of Heteroarotinoids Demonstrate Structure Specificity Relationships
Benbrook, D. M., Subramanian, S., Gale, J. B., Liu, S., Brown, C. W., Boehm, M. F., & Berlin, K. D. (1998) · Journal of Medicinal Chemistry · doi:10.1021/jm980308p · Cited by 25
Expression of a recombinant dystrophin in mdx mice using adenovirus vector
Alameddine, H. S., Quantin, B., Cartaud, A., Dehaupas, M., Mandel, J., & Fardeau, M. (1994) · Neuromuscular Disorders · doi:10.1016/0960-8966(94)90020-5 · Cited by 25
Ifuku, M., Iwabuchi, K. A., Tanaka, M., Lung, M. S. Y., & Hotta, A. (2018) · Methods in molecular biology · doi:10.1007/978-1-4939-8651-4_12 · Cited by 25
Screening for antisense modulation of dystrophin pre-mRNA splicing
Dickson, G., Hill, V. J., & Graham, I. R. (2002) · Neuromuscular Disorders · doi:10.1016/s0960-8966(02)00085-8 · Cited by 24
“However, mutations that lead to in-frame deletions of up to 50% of the central part of the dystrophin molecule cause a milder myopathy, Becker muscular dystrophy (BMD), which can in some cases remain asymptomatic to old age [2,3].”
BackgroundKolwicz, S. C., Hall, J. K., Moussavi‐Harami, F., Chen, X., Hauschka, S. D., Chamberlain, J. S., Regnier, M., & Odom, G. L. (2019) · JACC Basic to Translational Science · doi:10.1016/j.jacbts.2019.06.006 · Cited by 29
Dystrophin in control and mdx retina
Zhao, J.-E., Uchino, M., Yoshioka, K., Miyatake, M., & Miike, T. (1991) · Brain and Development · doi:10.1016/s0387-7604(12)80123-9 · Cited by 24
“Recently, a very mild human muscular dystrophy patient with deletion of 46% of the dystrophin was reported [6].”
BackgroundGene therapy and molecular approaches to the treatment of hereditary muscular disorders
Fletcher, S., Wilton, S. D., & Howell, J. M. (2000) · Current Opinion in Neurology · doi:10.1097/00019052-200010000-00008 · Cited by 24
Therapeutic restoration of dystrophin expression in Duchenne muscular dystrophy
Wells, D. J. (2006) · Journal of Muscle Research and Cell Motility · doi:10.1007/s10974-006-9081-6 · Cited by 30
Specificity of dystrophin analysis improved with monoclonal antibodies
Ellis, J. M., Mân, N. T., Morris, G. E., Ginjaar, I. B., Moorman, A. F. M., & van Ommen, G. B. (1990) · The Lancet · doi:10.1016/0140-6736(90)92392-u · Cited by 24
Genome Editing in Neurosciences
Jaenisch, R., Gage, F. H., & Zhang, F. (2017) · Research and perspectives in neurosciences · doi:10.1007/978-3-319-60192-2 · Cited by 24
Gene therapy for Duchenne muscular dystrophy: an update on the latest clinical developments
Mbakam, C. H., & Tremblay, J. P. (2023) · Expert Review of Neurotherapeutics · doi:10.1080/14737175.2023.2249607 · Cited by 23
“The concept of mini-or micro-dystrophin was initially inspired by Becker muscular dystrophy (BMD) cases with mild phenotypes, carrying large in-frame exon deletions in the DMD gene [18].”
BackgroundProgressive muscular dystrophies
Chelly, J., & Desguerre, I. (2013) · Handbook of clinical neurology · doi:10.1016/b978-0-444-59565-2.00006-x · Cited by 23
Lin, A. Y., Próchniewicz, E., Henderson, D. M., Li, B., Ervasti, J. M., & Thomas, D. D. (2012) · Journal of Molecular Biology · doi:10.1016/j.jmb.2012.04.005 · Cited by 30
Wasala, N. B., Shin, J., Lai, Y., Yue, Y., Montanaro, F., & Duan, D. (2018) · Human Gene Therapy · doi:10.1089/hum.2017.144 · Cited by 24
“2 kb D17-48 minigene was found in a 61-yearold ambulant patient.(13) The Chamberlain lab optimized this 6.”
Transplantation of Retroviral Producer Cells for In Vivo Gene Transfer into Mouse Skeletal Muscle
Fassati, A., Wells, D. J., Walsh, F. S., & Dickson, G. (1996) · Human Gene Therapy · doi:10.1089/hum.1996.7.5-595 · Cited by 23
Vitiello, L., Mostacciuolo, M. L., Oliviero, S., Schiavon, F., Nicoletti, L., Angelini, C. I., & Danieli, G. A. (1992) · Journal of Medical Genetics · doi:10.1136/jmg.29.2.127 · Cited by 23
Chwalenia, K., Wood, M. J. A., & Roberts, T. C. (2025) · Journal of Muscle Research and Cell Motility · doi:10.1007/s10974-024-09688-2 · Cited by 27
“…muscular dystrophy is an allelic form of DMD characterised by later onset, milder disease severity, and slower disease progression, with many patients remaining ambulant well into adulthood (with some never requiring wheelchair use) (England et al. 1990; Clemens et al. 2020a; Thada et al. 2023).”
CRISPR applications for Duchenne muscular dystrophy: From animal models to potential therapies
Chey, Y. C. J., Arudkumar, J., Aartsma-Rus, A. M., Adikusuma, F., & Thomas, P. Q. (2022) · WIREs Mechanisms of Disease · doi:10.1002/wsbm.1580 · Cited by 28
“In contrast to DMD, mutations that cause BMD result in the expression of internally truncated but partially functional dystrophin at various levels (Aartsma-Rus et al., 2006; England et al., 1990).”
BackgroundNOX4 inhibition promotes the remodeling of dystrophic muscle
Hammers, D. W. (2022) · JCI Insight · doi:10.1172/jci.insight.158316 · Cited by 24
“If successful, these therapies will transform 272 DMD into a slower progressing disease that still exhibits progressive replacement of muscle with 273 ECM, which is seen in Becker muscular dystrophy patients (47, 48).”
BackgroundMolecular mechanisms and therapeutic strategies for neuromuscular diseases
Zambon, A. A., Falzone, Y., Bolino, A., & Previtali, S. C. (2024) · Cellular and Molecular Life Sciences · doi:10.1007/s00018-024-05229-9 · Cited by 26
“A key point is that the large central rod domain is particularly resilient to large in-frame deletions, as demonstrated by mildly-affected patients harboring large in-frame deletions affecting up to 46% of the coding sequence [168].”
BackgroundSwiderski, K., Shaffer, S. A., Gallis, B. M., Odom, G. L., Arnett, A. L. H., Edgar, J. S., Baum, D. M., Chee, A., Naim, T., Gregorevic, P., et al. (2014) · Human Molecular Genetics · doi:10.1093/hmg/ddu388 · Cited by 25
Luetschg, J., & Weis, J. (2006) · Swiss Medical Weekly · doi:10.4414/smw.2006.11213 · Cited by 24
Physical properties of dystrophin rod domain
Kahana, E., Flood, G., & Gratzer, W. B. (1997) · Cell Motility and the Cytoskeleton · doi:10.1002/(sici)1097-0169(1997)36:3<236::aid-cm4>3.0.co;2-5 · Cited by 22
Gene therapy in Duchenne muscular dystrophy
Inui, K., Okada, S., & Dickson, G. (1996) · Brain and Development · doi:10.1016/0387-7604(96)00043-5 · Cited by 22
“3 kb dystrophin cDNA derived from a patient with very mild BMD [10] was incorporated into a retrovirus vector pBabe net, in which expression was driven by the constitutive promoter elements of the Moloney”
Ho, P. P.-K., Lahey, L. J., Mourkioti, F., Kraft, P. E., Filareto, A., Brandt, M., Magnusson, K. E. G., Finn, E. E., Chamberlain, J. S., Robinson, W. H., et al. (2018) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1808648115 · Cited by 22
“A minidystrophin gene, which ranges between 6 and 8 kb in size, was identified in a family with mild DMD and results in expression of one-half the size of full-length dystrophin, but is still too large to be packaged into a single recombinant adenoassociated viral (rAAV) vector (10, 11).”
BackgroundBuscara, L., Gross, D., & Danièle, N. (2020) · Journal of Personalized Medicine · doi:10.3390/jpm10040258 · Cited by 22
“The observation that the deletion of a large part of the central domain leads to a very mild phenotype in patients set the ground for a large number of therapeutic trials aiming at expressing dystrophin forms shortened in the spectrin-like region [19].”
BackgroundMitrpant, C., Fletcher, S., & Wilton, S. D. (2009) · Current Molecular Pharmacology · doi:10.2174/1874-470210902010110 · Cited by 21
Review of Phase II and Phase III clinical trials for Duchenne muscular dystrophy
Scully, M. A., Pandya, S., & Moxley, R. T. (2012) · Expert Opinion on Orphan Drugs · doi:10.1517/21678707.2013.746939 · Cited by 26
“This is in contrast to patients with the less severe phenotype, Becker muscular dystrophy (BMD), who have in-frame mutations resulting in a truncated but functional protein [24-28].”
ResultTucker, J. D., Lu, P., Xiao, X., & Lu, Q. L. (2018) · Molecular Therapy — Nucleic Acids · doi:10.1016/j.omtn.2018.02.008 · Cited by 22
“The use of truncated forms of dystrophins is initially rationalized from the observation that dystrophin with in-frame deletion mutations can be associated with mild Becker muscular dystrophy (BMD).(42) The mini- and micro-dystrophins therefore can be considered as mutant forms of dystrophin with reduced function, and…”
BackgroundBourdon, A., François, V., Zhang, L., Lafoux, A., Fraysse, B., Toumaniantz, G., Larcher, T., Girard, T., Ledevin, M., Lebreton, C., et al. (2022) · Gene Therapy · doi:10.1038/s41434-022-00317-6 · Cited by 24
“Report of ≈46% shortened dystrophin in a 61-year-old ambulatory patient with Becker muscular dystrophy (BMD) [64] led to the design of MD transgenes that are compatible with additive gene therapy using rAAV vectors.”
MethodInfluentialTroponin T is capable of binding dystrophin via a leucine zipper
Pearlman, J. A., Powaser, P. A., Elledge, S. J., & Caskey, C. T. (1994) · FEBS Letters · doi:10.1016/0014-5793(94)01119-2 · Cited by 21
Development of Therapeutic RNA Manipulation for Muscular Dystrophy
Saifullah, S., Motohashi, N., Tsukahara, T., & Aoki, Y. (2022) · Frontiers in Genome Editing · doi:10.3389/fgeed.2022.863651 · Cited by 22
Gene and splicing therapies for neuromuscular diseases
Goyenvalle, A. (2015) · Frontiers in bioscience · doi:10.2741/4367 · Cited by 27
Oligonucleotide-mediated gene therapy for muscular dystrophies
Rando, T. A. (2002) · Neuromuscular Disorders · doi:10.1016/s0960-8966(02)00083-4 · Cited by 20
Sweeney, H. L., Masiero, S., & Carraro, U. (2022) · European Journal of Translational Myology · doi:10.4081/ejtm.2022.10440 · Cited by 21
Personalized exon skipping strategies to address clustered non-deletion dystrophin mutations
Forrest, S., Meloni, P. L., Muntoni, F., Kim, J., Fletcher, S., & Wilton, S. D. (2010) · Neuromuscular Disorders · doi:10.1016/j.nmd.2010.07.276 · Cited by 21
“Individuals lacking up to 67% of the central rod domain have been described with a mild BMD phenotype [17,18], indicating that certain dystrophin domains are not essential for near-normal function [17,19,20].”
Self-citationRagot, T., Opolon, P., & Perricaudet, M. (1997) · PubMed · Cited by 20
Very small dystrophin molecule in a family with a mild form of Becker dystrophy
Morandi, L. O., Mora, M., Bernasconi, P., Mantegazza, R., Gebbia, M., Balestrini, M. R., & Cornelio, F. (1993) · Neuromuscular Disorders · doi:10.1016/0960-8966(93)90043-j · Cited by 19
Larochelle, N., Oualikene, W., Dunant, P., Massie, B., Karpati, G., Nalbantoglu, J. N., & Lochmüller, H. (2002) · Biochemical and Biophysical Research Communications · doi:10.1006/bbrc.2002.6715 · Cited by 19
Genetic strategies for therapy of Duchenne muscular dystrophy
Łoboda, A., Chamberlain, J. S., & Dulak, J. (2025) · Molecular Therapy — Nucleic Acids · doi:10.1016/j.omtn.2025.102759 · Cited by 20
“159 The approach has been initially tested in young, 8-week-old mdx 4cv mice.”
Hanson, B., Stenler, S., Ahlskog, N., Chwalenia, K., Svrzikapa, N., Coenen-Stass, A. M. L., Weinberg, M. S., Wood, M. J. A., & Roberts, T. C. (2022) · Molecular Therapy — Nucleic Acids · doi:10.1016/j.omtn.2022.10.010 · Cited by 19
Assessment of Therapeutic Potential of a Dual AAV Approach for Duchenne Muscular Dystrophy
Albini, S., Palmieri, L., Dubois, A., Bourg, N., Lostal, W., & Richard, I. (2023) · International Journal of Molecular Sciences · doi:10.3390/ijms241411421 · Cited by 21
“The initial discovery that truncated dystrophins are still functional [6] provided the rationale to use smaller versions of dystrophin, fitting with AAVs capacity, that are currently being investigated in clinical trials.”
BackgroundImmunostaining of Dystrophin and Utrophin in Skeletal Muscle of Dystrophinopathies.
Sahashi, K., Ibi, T., Hiroshi, S. U. O. H., Nakao, N., Tashiro, M., Marui, K., Arahata, K., & Sugita, H. (1994) · Internal Medicine · doi:10.2169/internalmedicine.33.277 · Cited by 18
Truncated dystrophins reduce muscle stiffness in the extensor digitorum longus muscle of mdx mice
Hakim, C. H., & Duan, D. (2012) · Journal of Applied Physiology · doi:10.1152/japplphysiol.00866.2012 · Cited by 24
“Some patients with BMD carry large in-frame rod-domain truncations, yet they show very mild muscular dystrophy (14).”
BackgroundDesign of Trans-Splicing Adeno-Associated Viral Vectors for Duchenne Muscular Dystrophy Gene Therapy
Lai, Y., Li, D., Yue, Y., & Duan, D. (2008) · Methods in molecular biology · doi:10.1007/978-1-59745-237-3_16 · Cited by 20
Dystrophin expression in the hair cells of the cochlea
Dodson, H. C., Piper, T. A., Clarke, J. D. W., Quinlivan, R. C. M., & Dickson, G. (1995) · Journal of Neurocytology · doi:10.1007/bf01257377 · Cited by 23
Duchenne Muscular Dystrophy Gene Therapy
Saad, F. A., Saad, J. F., Siciliano, G., Merlini, L., & Angelini, C. I. (2022) · Current Gene Therapy · doi:10.2174/1566523223666221118160932 · Cited by 19
Davies, K. E. (2013) · Clinical Medicine · doi:10.7861/clinmedicine.13-6-594 · Cited by 22
Self-citationThe dystrophin superfamily: variability and complexity
Fabbrizio, E., Pons, F., Robert, A., Hugon, G., Bonet-Kerrache, A. A., & Mornet, D. (1994) · Journal of Muscle Research and Cell Motility · doi:10.1007/bf00121067 · Cited by 19
Thanh, L. T., Mân, N. T., Hori, S., Sewry, C. A., Dubowitz, V., & Morris, G. E. (1995) · American Journal of Medical Genetics · doi:10.1002/ajmg.1320580217 · Cited by 17
Chamberlain, J. S. (1991) · Current Opinion in Genetics & Development · doi:10.1016/0959-437x(91)80033-i · Cited by 17
Myoblast transfer and gene therapy in muscular dystrophies
Pagel, C. N., & Morgan, J. E. (1995) · Microscopy Research and Technique · doi:10.1002/jemt.1070300604 · Cited by 17
Clinical potential of microdystrophin as a surrogate endpoint
Boehler, J., Brown, K. J., Beatka, M. J., Gonzalez, J. P., Dreghici, R. D., Soustek-Kramer, M., McGonigle, S., Ganot, A., Palmer, T., Lowie, C., et al. (2022) · Neuromuscular Disorders · doi:10.1016/j.nmd.2022.12.007 · Cited by 22
“[66] England SB, Nicholson LV, Johnson MA, Forrest SM, Love DR, Zubrzycka-Gaarn EE, et al.”
Prime editing strategies to mediate exon skipping in DMD gene
Mbakam, C. H., Roustant, J., Rousseau, J., Yaméogo, P., Lu, Y., Bigot, A., Mamchaoui, K., Mouly, V., Lamothe, G., & Tremblay, J. P. (2023) · Frontiers in Medicine · doi:10.3389/fmed.2023.1128557 · Cited by 18
“Interestingly, the DMD gene is often still capable of producing a partially functional, albeit truncated, dystrophin protein following large DMD intragenic deletions as observed in some Becker muscular dystrophy (BMD), a form of muscular dystrophy with mild phenotype due to in-frame mutations in DMD gene (9, 10).”
BackgroundJørgensen, L. H., Larochelle, N., Orlopp, K., Dunant, P., Dudley, R., Stucka, R., Thirion, C., Walter, M. C., Laval, S. H., & Lochmüller, H. (2009) · Human Gene Therapy · doi:10.1089/hum.2008.162 · Cited by 18
“More importantly, several DMD patients with in-frame deletions of up to two thirds of the rod domain present with mild clinical Becker muscular dystrophy phenotypes (England et al. , 1990; Mirabella et al. , 1998), and thus our deletions were not thought to severely compromise dystrophin function.”
Darras, B. T., Menache-Starobinski, C. C., Hinton, V. J., & Kunkel, L. M. (2014) · Elsevier eBooks · doi:10.1016/b978-0-12-417044-5.00030-5 · Cited by 35
4. Gene Therapy of Duchenne Muscular Dystrophy
Fassati, A., Murphy, S. J., & Dickson, G. (1997) · Advances in genetics · doi:10.1016/s0065-2660(08)60449-6 · Cited by 16
Moreno, C., Arvanitakis, M., Deviere, J. M. E., & Gossum, A. V. (2005) · PubMed · Cited by 17
Simard, L. R., Gingras, F., Delvoye, N., Vanasse, M., Melan�on, S. B., & Labuda, D. (1992) · Human Genetics · doi:10.1007/bf00194314 · Cited by 17
“These mutations did not remove a critical domain as several deletions encompassing this region were shown to lead to a mild BMD phenotype (England et al. 1990; Koenig et al. 1989).”
BackgroundProspect of gene therapy for cardiomyopathy in hereditary muscular dystrophy
Yue, Y., Binalsheikh, I. M., Leach, S. B., Domeier, T. L., & Duan, D. (2015) · Expert Opinion on Orphan Drugs · doi:10.1517/21678707.2016.1124039 · Cited by 16
“48) are quite functional.[44] These mini-dystrophin genes are about 6–8-kb in length, and their expression in humans and animals has greatly mitigated skeletal”
BackgroundZimowski, J. G., Pilch, J., Pawelec, M., Purzycka, J., Kubalska, J., Ziora-Jakutowicz, K. N., Dudzińska, M., & Zaremba, J. (2017) · Journal of Applied Genetics · doi:10.1007/s13353-017-0391-8 · Cited by 15
“There are many examples of such reports: deletions of exons 17–48 (England et al. 1990); 1, 35– 44, 45–48, 48–51, 51 (Beggs et al.”
BackgroundDunckley, M. G., Wells, K. E., Piper, T. A., Wells, D. J., & Dickson, G. (1994) · Journal of Cell Science · doi:10.1242/jcs.107.6.1469 · Cited by 15
Shigihara-Yasuda, K., Tonoki, H., Goto, Y., Arahata, K., Ishikawa, N., Kajii, N., & Fujieda, K. (1992) · European Journal of Pediatrics · doi:10.1007/bf02073897 · Cited by 15
“Patients with BMD may show a patchy discontinuous pattern on dystrophin staining and/or a decreased quantity of dystrophin with or without changes in molecular weight [3, 7 , 14].”
BackgroundFortunato, F., Tonelli, L., Farnè, M., Selvatici, R., & Ferlini, A. (2024) · Frontiers in Neurology · doi:10.3389/fneur.2023.1288721 · Cited by 14
Gene therapy for Duchenne muscular dystrophy
Shimizu‐Motohashi, Y. (2025) · Brain and Development · doi:10.1016/j.braindev.2025.104424 · Cited by 19
The Muscular Dystrophies: Distinct Pathogenic Mechanisms Invite Novel Therapeutic Approaches
Sahenk, Z., & Mendell, J. R. (2011) · Current Rheumatology Reports · doi:10.1007/s11926-011-0178-6 · Cited by 18
“For example, a BMD patient with a deletion of exons 17 to 48 remained ambulatory until after age 61 years despite removing 46% of the coding region from the DMD gene [49].”
BackgroundAdenovirus-mediated In Vivo Gene Therapy
Perricaudet, M., & Stratford-Perricaudet, L. D. (1995) · Springer eBooks · doi:10.1007/978-94-011-0555-2_1 · Cited by 14
Klimchak, A. C., Sedita, L. E., Rodino‐Klapac, L. R., Mendell, J. R., McDonald, C. M., Gooch, K. L., & Malone, D. C. (2023) · Journal of Market Access & Health Policy · doi:10.1080/20016689.2023.2216518 · Cited by 16
“The clinical basis of the SRP-9001 dystrophin construct is based on the identification of a patient with Becker muscular dystrophy (BMD), who had an in-frame deletion of almost half of the DMD gene yet remained ambulant through 61 years of age [26].”
MethodPickart, A. M., Martin, A. S., Gross, B. N., Dellefave‐Castillo, L. M., McCallen, L. M., Nagaraj, C. B., Rippert, A. L., Schultz, C., Ulm, E. A., & Armstrong, N. (2024) · Journal of Genetic Counseling · doi:10.1002/jgc4.1892 · Cited by 13
“Relatively large lesions have been associated with milder phenotypes, including in a family with nearly half of the coding sequence deleted (England et al., 1990; Nakamura et al., 2008 ).”
Dhoke, N. R., Kim, H., Azzag, K., Crist, S. B., Kiley, J., & Perlingeiro, R. C. R. (2024) · Cells · doi:10.3390/cells13110972 · Cited by 14
“Strikingly, certain individuals affected by these mutations show very mild symptoms, with maintenance of ambulance into their sixties [16].”
BackgroundGene therapy in Duchenne muscular dystrophy: Identifying and preparing for the challenges ahead
Heslop, E., Turner, C., Irvin, A., Muntoni, F., Straub, V. W., & Guglieri, M. (2020) · Neuromuscular Disorders · doi:10.1016/j.nmd.2020.10.001 · Cited by 15
“[5] England SB, Nicholson LV, Johnson MA, Forrest SM, Love DR,”
Molecular dissection of dystrophin identifies the docking site for nNOS
Harper, S. Q. (2012) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1220256110 · Cited by 13
“One BMD patient was famously ambulant well into his 60s, despite missing nearly two-thirds of the dystrophin rod domain (15).”
BackgroundIs there a future for the use of left ventricular assist devices in Duchenne muscular dystrophy?
Hayes, E. A., & Nandi, D. (2020) · Pediatric Pulmonology · doi:10.1002/ppul.25181 · Cited by 12
“forms where patients remain asymptomatic until the fifth decade of life.(3) Survival and quality of life for both muscular dystrophies have improved significantly over the past several decades with advancements in respiratory care and the increased use of glucocorticoids, which may mitigate the inflammatory‐mediated l…”
BackgroundPreclinical Studies for Gene Therapy of Duchenne Muscular Dystrophy
Odom, G. L., Banks, G. B., Schultz, B. R., Gregorevic, P., & Chamberlain, J. S. (2010) · Journal of Child Neurology · doi:10.1177/0883073810371006 · Cited by 14
“Mini-dystrophins with 8 or more spectrin-like repeats display nearly full function and are similar to the protein expressed in muscles of a patient with Becker muscular dystrophy who remained ambulatory into his 70s.(5) Microdystrophins with 4 or 5 repeats display surprisingly high, but not full, function, although pa…”
BackgroundAlternative splicing of dystrophin exon 4 in normal human muscle
Torelli, S., & Muntoni, F. (1996) · Human Genetics · doi:10.1007/bf02267079 · Cited by 12
DNA analysis in Turkish Duchenne/Becker muscular dystrophy families
Battaloğlu, E., Telatar, M., Deymeer, F., Serdaroğlu, P., Kuseyri, F., Özdemır, C., Apak, M. Y., & Tolun, A. (1992) · Human Genetics · doi:10.1007/bf00221954 · Cited by 12
“The facts that this deletion was within the region where most DMD deletions have been observed in all populations, but that it has not previously been reported, raised the question of whether it usually resulted in a normal or very mild disease phenotype, as has been reported for two other deletions (England et al. 19…”
ResultWasala, N. B., Yue, Y., Hu, B., Shin, J., Srivastava, A., Yao, G., & Duan, D. (2022) · Human Gene Therapy · doi:10.1089/hum.2022.181 · Cited by 11
“40,41 Based on clinical observations, abbreviated l Dys genes were developed to fit into the AAV vector, the only viral vector that can efficiently deliver a transgene to all muscles in thebody.”
Molecular-Targeted Therapy for Duchenne Muscular Dystrophy: Progress and Potential
Scimè, A., & Rudnicki, M. A. (2008) · Molecular Diagnosis & Therapy · doi:10.1007/bf03256275 · Cited by 12
Metadata
- Authors
- England, S. B., Nicholson, L. V. B., Johnson, M. A., Forrest, S. M., Love, D. R., Zubrzycka-Gaarn, E. E., Bulman, D. E., Harris, J. B., & Davies, K. E.
- Affiliations
- John Radcliffe Hospital (GB)
- Hospital for Sick Children (CA)
- Venue
- Nature
- Published
- 1990-01
- Volume
- 343
- Issue
- 6254
- Pages
- 180-182
- ISSN
- 0028-0836 (ISSN-L)
- 1476-4687
- OpenAlex
- W2058807250
- Cited by
- 623
- References
- 25
- Citations by year
- 2026: 18 · 2025: 21 · 2024: 20 · 2023: 17 · 2022: 20 · 2021: 17 · 2020: 24 · 2019: 16 · 2018: 20 · 2017: 18 · 2016: 20 · 2015: 23 · 2014: 16 · 2013: 17 · 2012: 22
- FWCI
- 10.27
- Type
- journal article
- Language
- en
- Open access
- closed
- Licence
- www.springer.com/tdm (tdm)
- Locations
- Nature (publishedVersion)
- PubMed (publishedVersion)
- Topics
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Muscle Physiology and Disorders
- Health Sciences › Medicine › Genetics (clinical) › Neurogenetic and Muscular Disorders Research
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Genetics › Genomics and Rare Diseases
- Keywords
- Becker muscular dystrophy, Duchenne muscular dystrophy, dystrophin gene deletion, dystrophin, X-linked inheritance, reading frame, gene therapy
- MeSH terms
- Chromosome Deletion, Exons, Female, Genes, Humans, Male, Middle Aged, Muscle Proteins, Muscles, Muscular Dystrophies, Nucleic Acid Hybridization, Pedigree, Protein Conformation, Reference Values, Blotting, Western, Restriction Mapping, Dystrophin
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.